BIOSCIENCE REPORTS, published by Portland Press Ltd, is a prestigious journal dedicated to advancing the fields of biochemistry, biophysics, cell biology, and molecular biology. Founded in 1981, the journal has established itself as a vital resource for researchers and professionals, boasting a significant impact factor and high rankings within its categories, including Q2 in Biochemistry and Q1 in Biophysics as of 2023. The journal’s commitment to high-quality, peer-reviewed research ensures that it remains an influential platform for the dissemination of cutting-edge scientific findings. While it operates under a traditional subscription model, it offers various access options to accommodate the needs of the scientific community. With ongoing publication through 2024, BIOSCIENCE REPORTS continues to play a crucial role in shaping discussions in the life sciences and fostering innovative research in biology.

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

Acta Physiologica is a premier, peer-reviewed journal published by WILEY, dedicated to the dissemination of high-quality research across the field of physiology. With an impressive impact factor reflective of its Q1 category ranking in Physiology for 2023, this journal is a vital resource for researchers, professionals, and students alike, seeking to explore the complexities of biological systems. The journal is indexed with a commendable Scopus rank of #18 out of 193 in its category, placing it within the top 10% of its field, which underscores its influence and citation frequency within the academic community. Acta Physiologica publishes a variety of articles that address fundamental physiological concepts, innovative methodologies, and cross-disciplinary research. With its open access options, the journal ensures that cutting-edge knowledge is readily accessible, fostering an environment of collaboration and advancement in the study of physiology. Spanning from 2006 to 2024, the journal continues to be at the forefront of physiological research and education, encouraging the global sharing of knowledge through its comprehensive content.

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY is a distinguished publication presented by the POLISH PHYSIOLOGICAL SOC, dedicated to advancing the fields of physiology and pharmacology. Since its inception in 1991, this journal has maintained a commitment to disseminating vital research findings, contributing to the growing body of knowledge essential for understanding complex biological systems and their interactions with pharmacological agents. With a consistent focus on interdisciplinary studies, the journal holds a Q3 categorization in both Medicine and Pharmacology as well as Physiology for 2023, reflecting its relevance in these crucial fields. Although specific access options are not available, the journal's robust indexing and rankings in Scopus signify its credibility and the high caliber of its contributions, appealing to researchers, professionals, and students alike. Operating from the picturesque Jagiellonian University in Krakow, Poland, this journal not only enriches the academic landscape but also fosters global collaboration and innovation in the life sciences.

CHINESE JOURNAL OF PHYSIOLOGY, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, has been a vital resource since its inception in 1971, catering to the expansive field of physiology. Operating out of Taiwan, this journal addresses critical research in both general and medical physiology, providing a platform for innovative studies that contribute significantly to the understanding of biological processes. With an emphasis on disseminating high-quality, peer-reviewed articles, it holds a Q4 ranking in Physiology and a Q3 ranking in Medical Physiology as of 2023, reflecting its commitment to advancing physiological science. The ISSN for this journal is 0304-4920 and the E-ISSN is 2666-0059. While access options are not available as open access, researchers and professionals can still benefit from its valuable insights. Notably, it ranks #78/113 in Medicine - Physiology and #159/193 in Biochemistry, Genetics, and Molecular Biology - Physiology on Scopus, indicating its growing influence in the scientific community. We invite researchers, professionals, and students alike to explore the wealth of knowledge featured within the pages of the CHINESE JOURNAL OF PHYSIOLOGY.

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

LIFE SCIENCES, published by PERGAMON-ELSEVIER SCIENCE LTD, is an esteemed international journal that has been advancing the field since its inception in 1962. With an ISSN of 0024-3205 and an E-ISSN of 1879-0631, it serves as a critical forum for researchers, professionals, and students within the realms of biochemistry, genetics, molecular biology, medicine, and pharmacology. Currently ranked in the Q1 category across multiple disciplines, including a remarkable 2nd rank in General Pharmacology, Toxicology, and Pharmaceutics, the journal maintains a prestigious position in academic circles, evidenced by its high impact factor and significant percentile ranks. While LIFE SCIENCES is not an open-access journal, it remains dedicated to publishing high-quality, peer-reviewed research that pushes the boundaries of knowledge and fosters innovation. With converged research interests leading into 2024, LIFE SCIENCES continues to be a pivotal resource for the dissemination of influential findings, making it an indispensable tool for those engaged in the life sciences.